The effect of XXXX supplements on plasma @entity219 and @entity920 levels and the reported symptoms in healthy volunteers.

@entity1 @entity390 @entity146 @entity219 @entity920 @entity1277 @entity10 @entity5937
Information from animal studies has demonstrated the harmful effects of @entity219 supplementation on @entity920 transport. Although some studies have been carried out in @entity1 , the effect on @entity1 has not been as well documented as the effect on animals. Forty-seven healthy volunteers (26 @entity1 and 21 @entity1 ) took part in a double-blind cross-over trial which lasted for 12 weeks. The subjects were asked to take 50 mg of elemental @entity219 (as 220 mg @entity5937 ) or placebo, three times a day for six weeks. Venous blood was collected for the analysis of plasma levels of @entity920 and @entity219 . Symptoms, which included @entity10 , abdominal cramps, @entity390 , @entity1277 , were registered from 84% of @entity1 and 18% of @entity1 . Six female volunteers discontinued the trial; five owing to @entity146 and one owing to consistent @entity10 . Plasma @entity219 levels rose significantly in both @entity1 and @entity1 , the increase being 36% and 57%, respectively. Plasma @entity920 levels did not change significantly. Our study suggests that the gastric discomfort that is associated with @entity219 supplementation may be related to body weight as symptoms were reported from the lower-weight volunteers. Our study also shows no detrimental effect of 150 mg of @entity219 a day on plasma @entity920 levels in healthy volunteers over a period of six weeks.
